Amgen (AMGN) Receives Price Target

Amgen (AMGN) : The consensus price target for Amgen (AMGN) is $186.27 for the short term with a standard deviation of $16.14. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $209, however, the pessimist price target for the company is $157.

Amgen (AMGN) : 15 analysts are covering Amgen (AMGN) and their average rating on the stock is 2.37, which is read as a Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Amgen (AMGN) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 10 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.


Also, Gabelli & Co. initiates coverage on Amgen (NASDAQ:AMGN) . Analysts at the Gabelli & Co. have a current rating of Hold on the shares. The rating by the firm was issued on August 26, 2016.

Amgen (NASDAQ:AMGN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $170.55 and $168.62 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $170.56. The buying momentum continued till the end and the stock did not give up its gains. It closed at $170.13, notching a gain of 0.04% for the day. The total traded volume was 1,876,141 . The stock had closed at $170.06 on the previous day.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.